Orphazyme A/S
ORPHY
Other OTC0.03
USD
-0.05
- -
Orphazyme A/S
ORPHY
(Other OTC)
Recent
price
0.03
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Strategic Partners A/S, formerly Orphazyme A/S, operates as a Danish investment holding company that forms strategic partnerships with businesses demonstrating significant potential, particularly in the biopharmaceutical sector; it takes active ownership roles to generate value through its expertise, while also investing in equity interests, properties, and other assets for returns. The company, founded in 2009 and headquartered at Lyskær 8A in Herlev, Denmark, previously focused on biopharmaceutical research and development of therapies targeting neurodegenerative orphan diseases through amplification of heat-shock proteins; its historical main product candidate was arimoclomol, advanced for indications including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. In May 2022, the company sold substantially all of its biopharmaceutical assets and business activities to KemPharm Denmark A/S, a subsidiary of KemPharm Inc., for $12.8 million in cash plus assumption of approximately $5.2 million in liabilities, after which it ceased operational biotech activities and retained no material ongoing operations in that field. A new board and management team assumed control in May 2023, followed by approval of a new corporate strategy and name change from Orphazyme A/S to Strategic Partners A/S at an extraordinary general meeting in October 2024, with the rebranding effective October 24, 2024, and ticker symbol updated to STRAP on Nasdaq Copenhagen. The firm now emphasizes biopharmaceutical partnerships, exemplified by its February 2024 investment in Combigene A/S, a Swedish gene therapy company.